Characterizing caspase-1 involvement during esophageal disease progression.


Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 20 02 2020
accepted: 19 06 2020
pubmed: 3 7 2020
medline: 15 12 2020
entrez: 3 7 2020
Statut: ppublish

Résumé

Barrett's esophagus (BE) is an inflammatory condition and a neoplastic precursor to esophageal adenocarcinoma (EAC). Inflammasome signaling, which contributes to acute and chronic inflammation, results in caspase-1 activation leading to the secretion of IL-1β and IL-18, and inflammatory cell death (pyroptosis). This study aimed to characterize caspase-1 expression, and its functional importance, during disease progression to BE and EAC. Three models of disease progression (Normal-BE-EAC) were employed to profile caspase-1 expression: (1) a human esophageal cell line model; (2) a murine model of BE; and (3) resected tissue from BE-associated EAC patients. BE patient biopsies and murine BE organoids were cultured ex vivo in the presence of a caspase-1 inhibitor, to determine the importance of caspase-1 for inflammatory cytokine and chemokine secretion.Epithelial caspase-1 expression levels were significantly enhanced in BE (p < 0.01). In contrast, stromal caspase-1 levels correlated with histological inflammation scores during disease progression (p < 0.05). Elevated secretion of IL-1β from BE explanted tissue, compared to adjacent normal tissue (p < 0.01), confirmed enhanced activity of caspase-1 in BE tissue. Caspase-1 inhibition in LPS-stimulated murine BE organoids caused a significant reduction in IL-1β (p < 0.01) and CXCL1 (p < 0.05) secretion, confirming the importance of caspase-1 in the production of cytokines and chemokines associated with disease progression from BE to EAC. Targeting caspase-1 activity in BE patients should therefore be tested as a novel strategy to prevent inflammatory complications associated with disease progression.

Identifiants

pubmed: 32613271
doi: 10.1007/s00262-020-02650-4
pii: 10.1007/s00262-020-02650-4
doi:

Substances chimiques

Caspase Inhibitors 0
Chemokine CXCL1 0
Cxcl1 protein, mouse 0
IL1B protein, human 0
IL1B protein, mouse 0
Inflammasomes 0
Interleukin-1beta 0
Casp1 protein, mouse EC 3.4.22.36
Caspase 1 EC 3.4.22.36

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2635-2649

Subventions

Organisme : H2020 Marie Skłodowska-Curie Actions
ID : 721906

Auteurs

Gillian Barber (G)

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
Department of Surgery, Trinity Translational Medicine Institute, Trinity College and St. James's Hospital Dublin, Dublin 8, Ireland.

Akanksha Anand (A)

Department of Internal Medicine, Technical University of Munich, Munich, Germany.
School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.

James J Phelan (JJ)

Department of Surgery, Trinity Translational Medicine Institute, Trinity College and St. James's Hospital Dublin, Dublin 8, Ireland.

Aisling B Heeran (AB)

Department of Surgery, Trinity Translational Medicine Institute, Trinity College and St. James's Hospital Dublin, Dublin 8, Ireland.

Ewelina Flis (E)

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.

Niamh E Clarke (NE)

Department of Surgery, Trinity Translational Medicine Institute, Trinity College and St. James's Hospital Dublin, Dublin 8, Ireland.

Jenny A Watson (JA)

Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin 9, Ireland.

Julia Strangmann (J)

Department of Internal Medicine, Technical University of Munich, Munich, Germany.

Brian Flood (B)

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.

Hazel O'Neill (H)

Department of Surgery, Trinity Translational Medicine Institute, Trinity College and St. James's Hospital Dublin, Dublin 8, Ireland.

Dermot O'Toole (D)

National Oesophageal and Gastric Centre, St. James's Hospital, Dublin 8, Ireland.

Finbar MacCarthy (F)

National Oesophageal and Gastric Centre, St. James's Hospital, Dublin 8, Ireland.

Narayanasamy Ravi (N)

Department of Surgery, Trinity Translational Medicine Institute, Trinity College and St. James's Hospital Dublin, Dublin 8, Ireland.
National Oesophageal and Gastric Centre, St. James's Hospital, Dublin 8, Ireland.

John V Reynolds (JV)

Department of Surgery, Trinity Translational Medicine Institute, Trinity College and St. James's Hospital Dublin, Dublin 8, Ireland.
National Oesophageal and Gastric Centre, St. James's Hospital, Dublin 8, Ireland.

Elaine W Kay (EW)

Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin 9, Ireland.

Michael Quante (M)

Department of Internal Medicine, Technical University of Munich, Munich, Germany.

Jacintha O'Sullivan (J)

Department of Surgery, Trinity Translational Medicine Institute, Trinity College and St. James's Hospital Dublin, Dublin 8, Ireland. osullij4@tcd.ie.

Emma M Creagh (EM)

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland. ecreagh@tcd.ie.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH